WilmerHale Advises Orna Therapeutics on $221M Series B Financing

WilmerHale Advises Orna Therapeutics on $221M Series B Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On August 16, 2022, Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular therapies, announced that it secured $221 million in a Series B funding round with contributions from Merck, with whom Orna entered into a collaboration agreement, and founding investors MPM Capital and BioImpact Capital. The financing will enable Orna to continue development of its circular lipid nanoparticle delivery platform and expand the reach of current RNA therapeutics.

The team representing Orna in its Series B financing was led by Rosemary G. Reilly, Rebecca Nauta, Jenna Ventorino, Nick Andreacchi, Meghan Walsh and Bill Caporizzo.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel